%0 Journal Article
%T Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America
%A Annia Cherrez
%A Blanca Mar¨ªa Morfin-Maciel
%A Edgar Emilio Matos Benavides
%A Emanuel Vanegas
%A German D. Ramon
%A Ivan Cherrez-Ojeda
%A Jonathan A. Bernstein
%A Jose Mori
%A Jos¨¦ Ignacio Larco Sousa
%A Luis Felipe Ensina
%A Marcus Maurer
%A Miguel Felix
%A P. Latour Staffeld
%A Paul Wilches C
%A R. Cardona Villa
%A Valeria L. Mata
%J Archive of "The World Allergy Organization Journal".
%D 2019
%R 10.1016/j.waojou.2019.100011
%X Updated urticaria guidelines recommend that patients should be assessed for disease activity, severity, control, and quality of life at baseline and follow up. Regarding treatment, guidelines consider second generation antihistamines as the cornerstone in therapy for chronic urticaria (CU), while other drugs, such as omalizumab, are conceived as second-line alternatives. In regards to omalizumab, despite advances in the management of CU, there are still open questions about timing, dosing, and objective measures for clinical response. This study was designed to portray the use of patient-reported outcomes (PROs) in chronic urticaria management, as well as the effectiveness and treatment patterns of omalizumab in CU, as seen in a real-life setting in Latin America
%K Chronic spontaneous urticaria
%K Patient-reported outcomes
%K Omalizumab
%K Quality of life
%K Latin America CU
%K chronic urticaria
%K LA
%K Latin America
%K PRO
%K patient-reported outcomes
%K UAS7
%K urticaria activity score 7
%K EAACI/GA2LEN/EDF/WAO
%K European Academy of Allergology and Clinical Immunology
%K Global Allergy and Asthma European Network
%K European Dermatology Forum and World Allergy Organization
%K MCID
%K minimal clinical important difference
%K UCT
%K urticaria control test
%K CU-Q2oL
%K chronic urticaria quality of life questionnaire
%K SD
%K standard deviation
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439401/